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APC = antigen-presenting cell; CCP = citrulline-modified peptides and proteins; CXCL = CXC ligand; GC = germinal center; GPI = glucose-6-
phosphate isomerase; IFN = interferon; IL = interleukin; RA = rheumatoid arthritis; RF = rheumatoid factor; SDF = stromal cell derived factor; TNF =
tumor necrosis factor.
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Introduction
IgG autoantibodies and immune complexes have long
been recognized as potent pathologic triggers of inflam-
matory responses. Early hypotheses regarding the patho-
genesis of rheumatoid arthritis (RA) were molded by
experimental models of immune complex disease. IgG
aggregates are abundant in RA synovial fluids, and can
trigger complement activation. Hence, it seemed logical
that tissue damage in RA was attributable to the local
deposition of immune complexes.
Rheumatoid factors (RFs), which are autoantibodies spe-
cific for the constant regions of IgG, are detectable in
more than 80% of RA patients, and may also be present in
a ‘hidden’ or complexed form in the synovial fluids of some
seronegative patients. RFs efficiently fix and activate com-
plement  in vitro by the classic pathway [1]. In vivo
turnover studies of radiotagged complement proteins in
seropositive RA patients demonstrated that, compared
with control individuals, complement consumption was
greatly accelerated, especially at the extravascular sites of
inflammation [2]. Consistent with the notion that immune
complex formation was maximal at the synovial sites of
inflammation, complement activation was shown to be
much greater in RA synovial fluid than in blood [2–4].
Levels of C4 fragments at these sites also correlated with
titers of IgM RFs.
Infiltrating leukocytes are known to be recruited by the
downstream products of complement activation, espe-
cially the soluble anaphylatoxin C5a, with subsequent
enlistment of other components of the membrane attack
complex [5,6]. Flares of clinical activity in RA correlate
with increased levels of RF secreting cells, which are
especially prevalent in the bone marrow and synovial fluid
of RA patients [7].
IgM RFs have been reported to account for more than
10% of local plasma cells in RA synovia [8,9]. However,
infusions of RF into healthy individuals causes neither sus-
tained nor transient synovitis [10], indicating that RF
autoantibodies by themselves are not pathogenic. Never-
theless, IgM-RF-containing immune complexes may also
include IgG antibodies and unidentified peptides, which
could derive from self or exogenous antigens. In addition,
the recently resolved crystallographic structure of a human
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Abstract
B lymphocytes play several critical roles in the pathogenesis of rheumatoid arthritis. They are the
source of the rheumatoid factors and anticitrullinated protein antibodies, which contribute to immune
complex formation and complement activation in the joints. B cells are also very efficient antigen-
presenting cells, and can contribute to T cell activation through expression of costimulatory molecules.
B cells both respond to and produce the chemokines and cytokines that promote leukocyte infiltration
into the joints, formation of ectopic lymphoid structures, angiogenesis, and synovial hyperplasia. The
success of B cell depletion therapy in rheumatoid arthritis may depend on disruption of all these
diverse functions.
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IgM RF–Fc co-complex revealed that contacts with IgG
antigen involved only the periphery of the antigen-binding
cleft of the autoantibody [11]. These findings may indicate
that RA RF is capable of binding IgG as well as another
self or foreign antigen. Thus, although RF alone is not
proinflammatory, RF associated with immune complexes
can enhance local inflammatory processes, and there is
compelling clinical evidence that RFs contribute to extra-
articular disease.
Antigen-presenting function of B cells
In addition to being the precursors of antibody-secreting
plasma cells, the B cells in RA can play a critical role in the
afferent arm of the immune response (Table 1). Thus,
B cells can act as highly efficient antigen-presenting cells
(APCs), supporting the activation of autoreactive T cells.
In fact, by virtue of the high affinity of a specific mem-
brane-associated immunoglobulin for antigen, an antigen-
specific B cell can take up, process, and present peptides
from nominal antigen with 1000-fold or greater efficiency
than a ‘professional’ APC. In addition, activated B cells
can synthesize cytokines and membrane-associated mole-
cules that provide nonspecific help to adjacent T cells.
Strong experimental support for a central role of B cells in
RA pathogenesis, independent of antibody formation,
came from studies of human synovium/SCID mouse
chimeras [12]. Those studies confirmed that the T cell
activation is B cell dependent, in that targeted deletion of
B cells impaired local T cell responsiveness, and APCs
other than B cells could not substitute for the maintenance
of T cell activation.
Role of B cells in murine models of
rheumatoid arthritis
Following the development of methods for introduction of
transgenes and for targeted gene disruption, in vivo
murine models have been developed that have enabled a
re-evaluation of the role of B cells in arthritis. The
KRN/NOD murine model has been particularly revealing,
because in these mice there is complete penetrance of a
genetically determined disease process that results in
severe distal joint inflammation, which emulates key fea-
tures of RA [13]. Moreover, development of the disease
involves the coordinated functions of both B cells and
T cells, because infusion of nondepleting antibody to CD4
blocks disease, and mice devoid of B cells also do not
develop disease [13]. A pathogenic role for IgG autoanti-
bodies to glucose-6-phosphate isomerase (GPI) has been
documented in the KRN/NOD model; it was found that
infusions of these autoantibodies into otherwise healthy
mice rapidly led to the development of synovitis [14].
However, arthritis was not induced by introduction of pre-
formed anti-GPI antibody–antigen complexes, which sug-
gested that joint disease can result when autoantibodies,
produced either locally or systemically, interact with anti-
gens on synovial surfaces to develop immune complexes
in situ. These locally formed immune complexes were
shown to be proinflammatory only if they involve antibod-
ies to two or more epitopes, and the more diverse the anti-
body response, the more efficient the recruitment of
proinflammatory factors [15], suggesting that a complex
IgG autoantigen lattice is required for the recruitment of
downstream inflammatory effectors.
Studies in the KRN/NOD model have also enabled a closer
dissection of the role of complement in the development of
immune complex mediated synovitis. Although anti-GPI
antibodies are prevalent in the circulation, disease is limited
to the joints, probably because only articular immune com-
plexes are efficient at fixing complement [14]. C4-deficient
KRN/NOD mice develop arthritis of the same severity as
do wild-type mice, whereas animals deficient in factor B of
the alternative complement pathway develop attenuated
disease or no arthritis at all [16,17]. In addition, a partial
dependence on C3 was also demonstrated [16], which is
consistent with the known role of C3 in the stabilization of
immune complexes. These findings have led to a revision of
the earlier notion that IgG immune complexes trigger
inflammation primarily by engagement of the classical
pathway of complement activation, because these murine
studies indicated that disease initiation instead may involve
the alternative pathway.
Although interactions between immune complexes and
cellular receptors for the Fc regions of IgG (FcγR) were
not considered in earlier clinical investigations of RA, the
recent characterization of these receptors and the avail-
ability of relevant murine model systems has permitted a
thorough examination of their impact on pathogenesis. The
three classes of Fcγ cell surface receptors, isolated based
on their capacity to bind IgG-containing immune complex,
are heterogeneous in their binding specificities for
IgG1–IgG4, and their intracellular signaling motifs that can
either activate or inhibit cellular effector functions.
Although mice with deficiencies in complement compo-
nents typically exhibit attenuated immune complex
Table 1
Major physiologic functions of B lymphocytes
Precursors of antibody producing plasma cells
Provide noncognate help for T cell activation
Efficient antigen-presenting cells, especially for recall antigens
Produce cytokines (i.e. IL-4 and IL-10) that support the survival other
mononuclear cells
Generate and respond to chemotactic factors responsible for
leukocyte migration and development of granulation tissue
Sustain immunologic memoryS3
mediated disease in relevant murine models, the loss of
activating FcγRIII completely ablates arthritis development
[18]. Connecting these model systems to clinical disease,
in vitro blockade of FcγRIIIA on human macrophages was
recently shown to prevent the release of tumor necrosis
factor (TNF)-α and induction of IL-1α in human
macrophages [19]. FcγRIII may be an especially important
mediator of immune complex induced tissue damage in
RA, because of the size and composition of immune com-
plexes that arise at sites of disease (discussed by
Edwards and coworkers [20]). In more recent studies,
C5a, acting through the C5a receptor, was shown to
exacerbate immune complex induced inflammatory
disease by altering the ratio of activating to inhibitory FcγR
on macrophages [21]. These studies demonstrated a
direct link between the C5a chemoattractant and FcγR
related mechanisms responsible for immune complex trig-
gered inflammatory responses.
These investigations of murine models of RA have led to a
revision of our understanding of the role of secreted
autoantibodies in RA. Complement alone may be inade-
quate to sustain chronic inflammatory responses to
immune complex deposition, because stimulatory and
inhibitory FcγR may in fact be the primary regulators of
subsequent immune responses (for review [21]). The host
response to immune complex functions in the joints  is crit-
ically dependent on interactions with cell surface FcγR on
B cells and macrophages.
Immune complexes and mast cells
Mast cells are prominent in the synovial infiltrates of many
RA patients [22], and these tissue associated infiltrating
cells express membrane associated FcR for IgE and IgG,
which enable triggering resulting from antigen-specific
(and perhaps nonspecific) immunoglobulin cross-linking.
In murine models of immune complex disease, the mast
cell has been shown to play a central role in immune
complex mediated joint inflammation [23]. Mast cells trig-
gered by immune complexes produce proinflammatory
cytokines and proteolytic enzymes at sites of cartilage ero-
sions [24]. The mast cells are also major sources of the
vasoactive and chemotactic factors that facilitate the
recruitment of other leukocytes to the synovial tissues.
KRN/NOD mice that lack mast cells are resistant to inflam-
matory and erosive arthritis induced by arthritogenic
serum [25]. Along with macrophages, mast cells can
release TNF-α and IL-1. For these reasons, the mast cell is
now appreciated to be a cellular link between B cells,
autoantibodies, complement, and other inflammatory medi-
ators that contribute to erosive arthritis.
Anti-GPI antibodies and rheumatoid arthritis
Based on the unexpected discovery that antibodies to GPI
can induce synovitis in healthy mice, several groups have
looked for a role for these autoantibodies in clinical
disease. GPI is a ubiquitous enzyme that is essential for
glucose metabolism in all cell types, and it therefore
cannot represent a tissue-specific antigen recognized as
part of an autoimmune disease that is limited to the joints.
A more likely scenario is that increased local cell turnover
results in the deposition of GPI along joint surfaces [14],
where it may be recognized by autoantibodies that enter
from the circulation. Although Schaller and coworkers [26]
reported increased anti-GPI antibody titers in 64% of 69
RA patients, but not in patients with Lyme disease or
Sjögren’s syndrome, these findings were not confirmed in
subsequent reports. In a recent flurry of studies, only a
small minority of RA patients had detectable levels of
autoantibodies to GPI, and there were no significant differ-
ences from patients with other types of joint diseases
[27—30]. However, it remains a possibility that anti-GPI
antibodies may be more common in RA patients with
extra-articular disease, and especially in patients with
Felty’s syndrome, which were highly represented in the
first reported clinical survey [26].
Antibodies against citrulline-modified
proteins
Many RA patients have circulating antibodies to autoanti-
gens other than IgG, including type II collagen, heat shock
proteins, proteoglycans, cartilage link protein, and heavy
chain binding proteins [31]. In some cases T cell reactivity
to the same antigens was demonstrated by in vitro prolif-
eration assays [32]. In certain instances experimental
immunization with the antigens in complete Freund’s adju-
vant can cause arthritis in rodent models [33]. However,
immune responses to each of these antigens have been
detected in only a minority of patients, and a causative role in
clinical disease has not been firmly established. Therefore, at
best, such joint-specific autoantibodies cannot account for
chronic inflammatory arthritis in most RA patients.
More prominent in RA are IgG antibodies to citrulline-mod-
ified peptides and proteins (CCP). Citrullination repre-
sents a post-translational modification due to the
enzymatic deamination of peptidyl arginine to peptidyl cit-
rulline. It has been shown that citrulline is the essential
antigen epitope recognized by anti-CCP antibodies,
antiperinuclear antibodies, as well as antibodies to keratin,
filaggrin, and Sa. In fact, one extensive study [34] con-
cluded that although RF may be a more sensitive test for
RA, detection of anti-CCP antibodies is more than 90%
specific for the diagnosis of RA. Hence, the available evi-
dence supports a role for serologic testing for anti-CCP
antibodies as an aid in the diagnosis of RA, especially at
early stages of disease [35,36].
Although the biologic significance of anti-CCP antibodies
is unclear, citrullination may be a byproduct of abnormal
protein metabolism occurring at in vivo sites of increased
or abnormal apoptosis [37]. The B lymphocytes from RA
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patients are resistant to certain apoptotic stimuli [38],
which may reflect prosurvival signals delivered from syn-
ovial or bone marrow stromal cells [39]. Notably, increased
production of citrullinated peptide autoantibodies has been
demonstrated in two murine model systems of autoimmu-
nity with abnormalities in B cell apoptosis, whereas anti-
CCP responses were not associated with other
autoimmune models that included the classical collagen-
induced arthritis system [40]. These findings may suggest
that the generation of autoantibodies to citrulline related
neoantigens could be closely linked to mechanisms
responsible for impaired lymphocyte clonal regulation [34].
Citrullination of proteins may also have the potential to
contribute directly to the autoimmune response [41]. An
unexpected mechanistic linkage was found in studies of
mice transgenic for the human HLA-DRB1*0401 MHC
class II molecule, which contains the ‘shared epitope’ – a
well studied genetic susceptibility factor for RA. In vitro
incubation of transgenic B cells and macrophages with
citrulline-containing peptides resulted in enhanced
peptide side chain interactions with the shared epitope
that significantly increased peptide MHC affinity. More-
over, immunization of the HLA-DRB1*0401 transgenic
mice led to greatly enhanced in vitro recall responses to
synthetic citrullinated self peptides [41]. These observa-
tions suggest a new mechanism by which the ‘shared
epitope’ can predispose to RA.
Ectopic lymphoid tissue in rheumatoid
arthritis
About 60% or more of the synovial samples from RA
patients have infiltrates of B and T lymphocytes. Three
separate patterns of infiltrates have been described:
diffuse lymphocytic infiltrates with interdigitating dendritic
cells and variable amounts of B cells; aggregates of infil-
trating B and T cells in more substantial numbers, associ-
ated with interdigitating dendritic cells in disorganized
groupings; and T cells and B lymphocytes clustered in
aggregates arrayed around interdigitating dendritic cells
and associated with follicular dendritic cell networks. In
this latter pattern, which is present in less than one-third of
patients, the synovial cellular infiltrates appear to be orga-
nized into distinct B cell follicle-like structures in close
spatial relationship to CD4+ T cells and CD8+ T cells. In
general, these histologic features are similar to the germi-
nal center (GC) reactions that arise in peripheral lymphoid
tissues during antigen-specific responses after immuniza-
tion [42]. Immunohistochemical analyses have also shown
that within the lymphocytic infiltrates in the synovial tissue,
plasma cells may be organized in concentric rings around
large cellular clusters of T cells and CD20+ B cells, or as
perivascular clusters [43]. In addition, B cells and T cells
in rheumatoid synovial samples may bear the proliferation
associated cell marker Ki-67. This antigen has been
detected primarily on lymphocytes in the GC-like pattern
[44], but concurrent mitotic figures in RA synovial intima
are very low, suggesting that local B or T cell proliferative
expansions may be quite limited and/or that expression of
this marker is not synonymous with proliferation. Moreover,
B cell proliferation in ectopic lymphoid infiltrates has been
seen mainly in the network of the follicular dendritic cell,
whereas in human tonsilar GC reactions proliferation occurs
in a separate dark zone [45]. These findings suggest that
ectopic GC-like structures have functional and organiza-
tional differences from their physiologic analogs.
Although the presence of lymphoid infiltrates generally
correlates with clinical disease in RA, there is currently
limited information regarding the natural history of these
histologic patterns [46], and it is unknown whether a par-
ticular histologic pattern has implications for prognosis or
treatment responsiveness. Furthermore, although the dis-
eased joints in RA patients may have organized lymphoid
infiltrates that emulate physiologic peripheral lymphoid
tissues, it is still not clear that these changes are entirely
specific for RA. The affected joints of patients with anky-
losing spondylitis have also been shown at times to harbor
GC-like aggregates [47]. Even the synovia from
osteoarthritic joints can occasionally contain infiltrates of
activated B cells and plasma cells exhibiting clonally
related antibody gene sequences [48,49]. In addition, lym-
photoxin-β (LT-1β2), which is produced by activated
T cells, may be a downstream effector that is required for
the development of primary B cell follicles in the synovial
infiltrates [50–52]. Rheumatoid synovial tissues have also
unexpectedly been found to be rich sources of CXCL12
(also termed stromal cell derived factor [SDF]-1) [53]. In
fact, SDF-1 produced by fibroblast-like synoviocytes has
been shown to contribute to the resistance of B cells to
apoptosis, which supports an earlier hypothesis that spe-
cialized synovial ‘nurse-like cells’ peculiar to RA synovium
mediate homing and survival of B cells [54]. In recent
studies plasma cells have also been shown to migrate
toward gradients of SDF-1 [55], CXCL9 (monokine
induced by IFN-γ), CXCL10 (IFN-γ-inducible protein 10),
and CXCL11 (IFN-inducible T cell α chemoattractant)
[55]. SDF-1, as well as IL-5, IL-6, TNF-α, and ligands for
CD44, can also prolong the longevity of plasma cells [56].
In addition, the TNF-α family member B lymphocyte stimu-
lator (BLyS, also called Baff) has also recently been
detected at high levels in rheumatoid synovial fluid, sug-
gesting that this prosurvival factor can also be locally pro-
duced in inflamed joints [57].
The dysregulated expression of cytokines and costimula-
tory molecules explains the reported accumulation in one-
third of RA samples of an unusual subpopulation of
peripheral B cells with a restricted immunoglobulin vari-
able region gene repertoire that coexpress conventional
light chains and the surrogate light chain of pre-B cells
[58]. Such B lineage cells have been postulated to be
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promiscuous in antigen presentation, and thus could
present diverse autoantigens. This topic is still highly con-
troversial because other investigators have not found
these B lineage cells in healthy tissues, and have chal-
lenged the authenticity of their reported phenotype [59].
The imprint of the potent chemoattractive activating and
antiapoptotic factors described above may largely explain
the skewed distribution of the B lymphoid cells that accu-
mulate in the synovium. The local production of these
factors at sites of inflammation in RA joints may serve as
beacons to foster B cell accumulation, proliferation, and
differentiation. An active (auto)antigen driven GC reaction
may not be required to explain the development of the
ectopic B lymphoid infiltrates in the joints of RA patients.
Conclusion
Recent reports have confirmed the importance of immune
complexes in the pathogenesis of RA, and have elucidated
additional critical roles for B cells and their immunoglobu-
lin products in self-sustaining chronic inflammatory
processes (Table 2). These findings have contributed to
the rationale for the development of targeted therapies
that delete B cells [60] or that attenuate the function of
secreted and membrane associated factors that con-
tribute to B cell accumulation and survival at sites of
disease [61]. However, an appreciation of these diverse
potential roles may also predict that the targeted interfer-
ence with just one B cell antigen or costimulatory mole-
cule may not be sufficient to arrest ongoing disease in all
RA patients.
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